Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report)'s share price was down 7.5% during trading on Thursday . The stock traded as low as $0.75 and last traded at $0.75. Approximately 209,762 shares traded hands during trading, an increase of 30% from the average daily volume of 160,889 shares. The stock had previously closed at $0.81.
Nautilus Biotechnology Trading Up 0.8%
The firm has a 50-day moving average of $0.76 and a 200 day moving average of $1.11. The company has a market cap of $99.37 million, a P/E ratio of -1.46 and a beta of 1.42.
Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. On average, equities analysts predict that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Presidio Capital Management LLC boosted its holdings in Nautilus Biotechnology by 246.6% in the second quarter. Presidio Capital Management LLC now owns 34,664 shares of the company's stock worth $25,000 after acquiring an additional 24,664 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Nautilus Biotechnology by 468.3% in the first quarter. Acadian Asset Management LLC now owns 61,735 shares of the company's stock worth $51,000 after acquiring an additional 50,871 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Nautilus Biotechnology in the first quarter worth approximately $194,000. Nuveen LLC purchased a new stake in shares of Nautilus Biotechnology in the first quarter worth approximately $167,000. Finally, Fayez Sarofim & Co purchased a new stake in shares of Nautilus Biotechnology in the first quarter worth approximately $39,000. Institutional investors own 50.71% of the company's stock.
About Nautilus Biotechnology
(
Get Free Report)
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
Featured Articles
Before you consider Nautilus Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nautilus Biotechnology wasn't on the list.
While Nautilus Biotechnology currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
